Background: There is currently no standard treatment for patients with castration-resistant prostate cancer (CRPC) whose disease progresses after docetaxel-based chemotherapy. The purpose of this study was to prospectively assess the anticancer activity and tolerance of the carboplatin-etoposide combination in this setting while evaluating neuroendocrine (NE) features.
introduction
Prostate cancer is the most commonly diagnosed cancer in men in the Western world and is the second leading cause of cancer deaths in males [1] . Although androgen deprivation therapy remains the mainstay of treatment for patients with metastases, the disease eventually progresses to castration-resistant prostate cancer (CRPC). In 2004, the results of two large randomised trials reported a significant improvement in overall survival (OS), time to disease progression, pain control, and prostatespecific antigen (PSA) response to docetaxel (alone or in combination with estramustine) compared with mitoxantrone [2, 3] . Since then, docetaxel-based chemotherapy has become the standard treatment in CRPC. Recently, data from a metaanalysis of individual data from randomised trials reported an improvement in OS when chemotherapy was combined with estramustine, as compared with chemotherapy alone [4] . Although docetaxel-based chemotherapy improves survival with about a 20% reduction in risk of death, patients eventually experience progression within a median of 7 months. There is currently no standard of treatment for patients who fail first-line docetaxel-based chemotherapy.
Neuroendocrine (NE) features have been reported to be associated with progression towards CRPC. The incidence of prostate cancer with NE differentiation ranges from 30% to 100% and this incidence is greater in CRPC [5] . Some preclinical studies also suggest that NE differentiation may promote progression to the castration-resistant state [6, 7] . Positive immunohistochemical staining for chromogranin A (CgA), a marker of NE differentiation, is an independent predictor of cancer progression in well-differentiated and moderately well-differentiated prostate cancers [8] .
original article Furthermore, serum CgA correlates with the number of CgApositive NE tumour cells [9] . NE cancer cells, unlike non-NE cancer cells, do not express the androgen receptor [10] . Androgen deprivation therapy maybe associated with NE differentiation [11] . NE cells that survive in the androgendeprived environment may establish paracrine networks to stimulate androgen-independent proliferation of the secretorytype cancer cells, leading to progressive CRPC [12] . Some studies have demonstrated that NE cells in prostate cancer produce interleukin (IL)-8 and that non-NE tumour cells express increased levels of the IL-8 receptor, CXCR1, suggesting that NE differentiation maybe one of the factors that contribute to the progression of prostate cancer in a paracrine fashion [13] . Recently, the chemosensitivity of CRPC to platinum agents was revisited and a large randomised phase III trial demonstrated that satraplatin, a new platin compound, could reduce the risk of disease progression for CRPC patients who have failed prior chemotherapy in comparison with those treated with placebo [14] . Etoposide is also an active drug in CRPC [15] , although it has never been tested prospectively in a randomised trial in this setting. Only a few studies have prospectively investigated the chemosensitivity of CRPC with NE features [16] . It is currently unknown whether docetaxel is as active in CRPC with NE features compared with CRPC devoid of NE features, and it is unknown whether anticancer drugs known to be active in poorly differentiated NE carcinomas are active in this subgroup of CRPC. The cisplatin or carboplatin and etoposide combination yields strong activity and is the standard treatment for poorly differentiated NE cancers, including smallcell lung cancer [17, 18] . Preclinical studies suggested synergistic activity when these two agents were combined in prostate cancer models [19] . We prospectively studied the activity of the carboplatin-etoposide regimen in patients previously treated with docetaxel-based chemotherapy and we investigated whether NE features were predictive of treatment activity.
patients and methods
eligibility
From January 2004 to December 2006, patients with CRPC and evidence of progression after first-line docetaxel-based chemotherapy and treated at the Institut Gustave Roussy, Villejuif, France, were proposed second-line carboplatin-etoposide and were prospectively registered. Inclusion criteria also included a performance status less than two or two, a castrated level of serum testosterone (<0.50 ng/ml), while on luteinising hormone releasing hormone agonist or after bilateral orchiectomy, adequate bone marrow, renal, and hepatic function [neutrophils 1.5 · 10 9 /l, platelets 100 · 10 9 /l, haemoglobin 10 g/dl, serum creatinine 1.5 · upper normal limit (UNL), bilirubin UNL, alanine aminotransferase, and aspartate aminotransferase 1.5 · UNL]. Serum CgA and serum neuron-specific enolase (NSE) were measured at baseline before chemotherapy. Serum CgA was evaluated by an immunoradiometric assay (CGA-RIACT) and NSE was evaluated using the ELISA-NSE immunoradiometric kit. Progression was defined according to the PSA Working Group consensus criteria [18] . Prostate cancer was defined as docetaxel resistant in case of progression within 60 days following docetaxel. Biphosphonates were allowed in patients presenting bone metastases.
treatment
Carboplatin was given to a target area under the plasma concentration versus time curve of 5 i.v. on day 1. Etoposide was given at a dose of 80 mg/m 2 /day for three consecutive days, as an i.v. infusion on day 1 and orally on days 2 and 3. This two-drug regimen was administered once every 3 weeks. Cycles were administered if the granulocyte count was >1500/mm 3 and platelets >100 000/mm 3 . Chemotherapy was administered until cancer progression, toxicity, or patient refusal. Granulocyte colony-stimulating factors were not used as primary prophylaxis. Recombinant erythropoietin or red blood cell transfusions were used if required. All patients were kept on androgen deprivation therapy.
response criteria and toxicity assessment
The performance status and pain were recorded at baseline and then every two cycles.
Patients underwent a physical examination, assessment of toxicity, blood counts, and serum biochemistry before each cycle. Blood counts were obtained every week to evaluate haematological toxicity. Patients were considered assessable for toxicity if they had received at least one dose of chemotherapy. Toxicity was defined using the National Cancer Institute-Common Toxicity Criteria version 2.0. Serum PSA was measured before treatment and every two cycles. In patients with measurable disease, computed tomography scan or magnetic resonance imaging was carried out every two cycles. PSA response was defined according to the guidelines of the PSA Working Group [20] . PSA response was defined as >50% decline from the baseline PSA level confirmed by a second PSA measurement. OS was calculated from the time of treatment initiation to death. Progression-free survival (PFS) was calculated from the time of treatment initiation to the first sign of progression documented by either PSA or imaging. Pain response was evaluated by a visual analog scale (ranging from 0 to 100 mm). Patients whose pain score showed a decrease of ‡20 mm were considered responders.
The effect of several baseline pretreatment variables on efficacy was evaluated, including serum CgA, serum NSE, and prostate-specific antigendoubling time (PSADT).
statistical analysis
Descriptive statistics were used to analyse patient characteristics [mean, median, 95% confidence intervals (CIs)]. PFS and OS were calculated using the Kaplan-Meier method and compared by the log-rank test. Univariate analysis was carried out to correlate baseline CgA, NSE, and PSADT with efficacy criteria. A P value of <0.05 was considered statistically significant for all comparisons. Table 1 .
efficacy
The median number of cycles of the carboplatin-etoposide combination was 3 (range 1-10). Only one patient discontinued chemotherapy due to toxicity. The median duration of chemotherapy was 2.1 months (range 0.6-9.6).
The median duration of follow-up was 15 months (range 2.1-27.7). A PSA response was obtained in nine patients [23% (95% CI 11% to 39%)] whereas 19 patients [48% (95% CI 32% to 64%)] experienced progression ( The median PFS was 2.1 months (range 0.6-9.6) and the median OS rate was 19 months (range 2.1-27.7). The 1-year survival rate was 77% (95% CI 62% to 87%) (Figures 1 and 2 ).
Three patients were lost to follow-up for the evaluation of OS. Of 28 patients assessable for the assessment of pain, 15 (54%) achieved a response.
correlation of NE features with treatment efficacy and the prognosis No significant association was found between baseline serum CgA or serum NSE and response to treatment or the prognosis (Table 3) . Patients with elevated CgA at baseline had a nonsignificantly higher response rate (31% versus 18%, P = n.s.). A higher baseline serum NSE level was not predictive Serum NSE before second-line chemotherapy <12.5 ng/ml 66% >12.5 ng/ml 34% Serum chromogranin A before second-line chemotherapy <10 2 ng/ml 55% >10 2 ng/ml 45% PSA-doubling time before second-line chemotherapy <2 months 63% >2 months 34%
PSA, prostate-specific antigen; NSE, neuron-specific enolase. for response (20% versus 25%, P = n.s.). PSADT was not predictive for response to treatment in this population.
tolerance Safety data were assessable in 40 patients and are listed in Table 4 . Overall, the carboplatin-etoposide regimen was well tolerated. The most common grades 3-4 toxicity was neutropenia which occurred in 15 patients (38%) but neutropenic fever was reported in only one patient (2%). There was no grade 3 or 4 thrombocytopenia. Ten patients (25%) experienced grades 3-4 anaemia. No treatment-related deaths occurred.
discussion
There is currently no standard treatment for patients exhibiting disease progression after first-line docetaxel-based chemotherapy. NE differentiation was purported to be associated with progression to CRPC [21, 22] . As preclinical and clinical data have evidenced synergistic activity of the carboplatin-etoposide combination, this regimen was assessed as second-line chemotherapy after treatment with docetaxel. This combination was active in patients with CRPC yielding a PSA decline of ‡50% in 22% and was also well tolerated. Activity was detected in CRPC with and without NE features.
The currently reported activity of other chemotherapeutic agents (such as mitoxantrone and navelbine) in patients with CRPC-exhibiting progression after docetaxel is low, with response rates ranging from 5% to 20% range (Table 5) . A randomised phase II trial recently reported a response rate of 17% and 20%, respectively, in 41 patients with taxanerefractory prostate cancer treated with ixabepilone and mitoxantrone-prednisone in the second-line setting [23] . The survival and PSA response of patients who crossed over to receive docetaxel after mitoxantrone or vice versa in the TAX 327 study were recently reported [24] . Median survival after crossover was 10 months and did not depend on the direction of the crossover. A PSA response ( ‡50% reduction) was achieved in 9% of 45 patients receiving mitoxantrone after docetaxel and 35% of 23 patients receiving docetaxel after mitoxantrone (P = 0.016). Another option is the reintroduction of docetaxel at progression after an initial response to docetaxel-based chemotherapy in a series of 31 patients, a PSA response was reported in 59% [25] . However, this strategy is less likely to be active in patients exhibiting disease progression within 3 months after completion of docetaxel (Y. Loriot et al., submitted). New agents are actively being tested in this setting. A phase III trial (SPARC) recently evaluated satraplatin, an orally bioavailable platinum compound, in the second-line setting [14] . About half of the 950 patients had received a docetaxel-based regimen as firstline therapy. Although a statistically significant improvement in PFS (defined as a radiologic progression, symptomatic progression, skeletal events, or death was reported), the trial failed to detect a benefit in OS. Therefore, although the use of second-line chemotherapy has not been fully validated in patients with CRPC, it is an option worth considering in fit patients. Moreover, before considering failure of second-line chemotherapy, physicians should be aware of the surge syndrome occurring independently of line of treatment to avoid inappropriate early discontinuation of chemotherapy: 20% of patients achieving a response or stabilisation had an initial serum PSA rise [26] .
Since NE features may contribute to progression to CRPC, we investigated whether serum markers of NE differentiation including CgA and NSE correlated with outcome. Increased serum CgA and NSE levels were found in 45% and 34% of cases, respectively. These findings are in accordance with the results reported by other studies which showed increased CgA in 43%-45% of patients with CRPC [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] . There was no significant association between baseline serum CgA or serum NSE and survival. Slightly higher albeit nonsignificant response to the carboplatin-etoposide regimen was observed in patients with elevated CgA at baseline (31% versus 18%). A previous study reported that response to a first-line estramustineetoposide and cisplatin or carboplatin regimen was not predicted by NE staining carried out on the metastatic tumour specimen [28] . In contrast, elevated serum CgA was predictive for activity of first-line paclitaxel-carboplatin or mitoxantrone regimen [27] . These conflicting results underline the need for larger prospective studies. The carboplatin and etoposide regimen had a palliative effect evidenced by the fact that half of the patients in this study achieved a pain response, assessed by a visual analog scale. This finding is particularly important because palliation is a critical end point in second-line chemotherapy in CRPC since to date no chemotherapy agent has demonstrated a survival benefit in this setting. This regimen was well tolerated with a low incidence of serious adverse events. The main toxic effects were haematological with only 2% of neutropenic fever. Only one patient discontinued treatment because of toxicity. Together with palliation, toxicity is also a key criterion in patients with progressive CRPC after docetaxel. Bearing these points in mind, the carboplatin and etoposide regimen appears to be a suitable option for these patients.
In conclusion, the carboplatin-etoposide regimen was well tolerated and yielded a PSA response of 23% in patients and a palliative effect in about half of the patients with progressive CRPC after docetaxel, making it a reasonable option in these patients in spite of a limited PFS. These results need a confirmatory study because of the limited number of patients and uncontrolled design of this study. No strong correlation between NE features and outcome was observed, and activity was detected both in tumours with and without NE features. Therefore, elevated baseline serum CgA or NSE should not be retained as criteria for the selection of CRPC patients for carboplatin-etoposide therapy.
acknowledgements
The authors thank Lorna Saint Ange for editing. 
references

